Introduction:
The pharmaceutical sector has seen exceptional stock performances over the past year, with certain companies delivering impressive multibagger returns of up to 200%. This growth has been fueled by strategic advancements and favourable market dynamics.
These remarkable returns have drawn significant attention from investors eager to explore growth opportunities in the pharma industry. With the potential for further expansion in the sector, it’s worth analysing these standout stocks and evaluating their place in your investment portfolio.
Neuland Laboratories Ltd
On December 20, 2024, Neuland Laboratories Ltd (BSE: NEULANDLAB) opened at ₹14,432.00, reached a high of ₹14,597.60, and a low of ₹13,970.00. The stock closed at ₹13,970.00, down by 3.19%. The company’s market capitalization stood at ₹17,923.35 crore.
Neuland Labs has shown strong growth with a 4.23% return over the past month, 146.41% over the last six months, and an impressive 217.17% return over the past year, highlighting its robust performance and potential for continued growth.
Neuland Labs is a leading player in the pharmaceutical industry, specialising in the manufacturing of Active Pharmaceutical Ingredients (APIs) and contract research. Known for its strong R&D capabilities, the company has shown impressive growth with consistent returns over the past year.
Supriya Lifescience Ltd
On December 20, Supriya Lifescience Ltd (BSE: SUPRIYA) opened at ₹763.95, reached a high of ₹782.95, and a low of ₹728.65. The stock closed at ₹728.65, down by 4.72%. The company’s market capitalization stood at ₹5,864.38 crore.
Supriya Lifescience Ltd has posted a remarkable 169.04% return over the past year and 89.82% over the last six months, with a solid 24.18% return in the past month, reflecting its strong growth trajectory and market performance.
Supriya Lifescience Ltd is a prominent manufacturer of active pharmaceutical ingredients (APIs) with a strong presence in the global market. The company has been growing steadily, driven by its focus on quality and customer satisfaction, reflecting in its solid performance over the past year.
Also Read: Tata group stock in focus after it partners with Canara bank for PM Surya Ghar Scheme
Windlas Biotech Ltd
On December 20, Windlas Biotech Ltd (BSE: WINDLAS) opened at ₹1,049.95, reached a high of ₹1,050.15, and a low of ₹1,034.75. The stock closed at ₹1,034.75, up by 0.81%. The company’s market capitalization stood at ₹2,168.83 crore.
Windlas Biotech Ltd has delivered an impressive 157.33% return over the past year and 46.12% over the last six months, with a positive 5.08% return in the past month, highlighting its consistent performance and growth potential.
Windlas Biotech Ltd is a leading contract manufacturer of pharmaceutical products, providing high-quality formulations to global markets. With a strong track record of growth, the company has consistently delivered solid returns, positioning itself as a key player in the biotech sector.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.
